RU2010114038A - Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза - Google Patents
Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза Download PDFInfo
- Publication number
- RU2010114038A RU2010114038A RU2010114038/15A RU2010114038A RU2010114038A RU 2010114038 A RU2010114038 A RU 2010114038A RU 2010114038/15 A RU2010114038/15 A RU 2010114038/15A RU 2010114038 A RU2010114038 A RU 2010114038A RU 2010114038 A RU2010114038 A RU 2010114038A
- Authority
- RU
- Russia
- Prior art keywords
- diseases
- gln
- disease
- phe
- lys
- Prior art date
Links
- 102000004379 Adrenomedullin Human genes 0.000 title 1
- 101800004616 Adrenomedullin Proteins 0.000 title 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 7
- 208000019693 Lung disease Diseases 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 7
- 206010016654 Fibrosis Diseases 0.000 claims abstract 6
- 208000035473 Communicable disease Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 230000004761 fibrosis Effects 0.000 claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 5
- 208000030159 metabolic disease Diseases 0.000 claims abstract 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims abstract 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 230000002792 vascular Effects 0.000 claims abstract 4
- 230000033115 angiogenesis Effects 0.000 claims abstract 3
- 210000004204 blood vessel Anatomy 0.000 claims abstract 3
- 230000001684 chronic effect Effects 0.000 claims abstract 3
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims abstract 2
- 208000030507 AIDS Diseases 0.000 claims abstract 2
- 200000000007 Arterial disease Diseases 0.000 claims abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 206010010356 Congenital anomaly Diseases 0.000 claims abstract 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract 2
- 206010023330 Keloid scar Diseases 0.000 claims abstract 2
- 208000000592 Nasal Polyps Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 206010029113 Neovascularisation Diseases 0.000 claims abstract 2
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 206010037649 Pyogenic granuloma Diseases 0.000 claims abstract 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims abstract 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims abstract 2
- 206010043189 Telangiectasia Diseases 0.000 claims abstract 2
- 208000009443 Vascular Malformations Diseases 0.000 claims abstract 2
- 206010047115 Vasculitis Diseases 0.000 claims abstract 2
- 210000000577 adipose tissue Anatomy 0.000 claims abstract 2
- 230000003872 anastomosis Effects 0.000 claims abstract 2
- 208000022531 anorexia Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 2
- 208000010668 atopic eczema Diseases 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 206010061428 decreased appetite Diseases 0.000 claims abstract 2
- 208000016097 disease of metabolism Diseases 0.000 claims abstract 2
- 208000030533 eye disease Diseases 0.000 claims abstract 2
- 208000019622 heart disease Diseases 0.000 claims abstract 2
- 201000011066 hemangioma Diseases 0.000 claims abstract 2
- 230000002008 hemorrhagic effect Effects 0.000 claims abstract 2
- 206010020718 hyperplasia Diseases 0.000 claims abstract 2
- 230000002390 hyperplastic effect Effects 0.000 claims abstract 2
- 210000002751 lymph Anatomy 0.000 claims abstract 2
- 210000001365 lymphatic vessel Anatomy 0.000 claims abstract 2
- 230000036244 malformation Effects 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 208000003154 papilloma Diseases 0.000 claims abstract 2
- 230000002085 persistent effect Effects 0.000 claims abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract 2
- 206010039083 rhinitis Diseases 0.000 claims abstract 2
- 208000017520 skin disease Diseases 0.000 claims abstract 2
- 208000011580 syndromic disease Diseases 0.000 claims abstract 2
- 208000009056 telangiectasis Diseases 0.000 claims abstract 2
- 208000019553 vascular disease Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 4
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 1
- 206010034650 Peritoneal adhesions Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010046788 Uterine haemorrhage Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 231100000516 lung damage Toxicity 0.000 claims 1
- -1 lyoprotector Substances 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 208000025661 ovarian cyst Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000006266 hibernation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
Abstract
1. Применение пептида Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из васкулита и избыточного ангиогенеза при аутоиммунных заболеваниях, системного склероза, рассеянного склероза, синдрома Шегрена, мальформаций сосудов в сетях кровеносных и лимфатических сосудов, синдрома ДиДжорджа, врожденной геморрагической телеангиэктазии, пещеристой гемангиомы, кожной гемангиомы, мальформаций лимфатических сосудов, артериопатий трансплантата, атеросклероза, анастомозов сосудов, жировой ткани при ожирении, хронического отторжения аллотрансплантата, болезней кожи, псориаза, папиллом, аллергического дерматита, келоидных рубцов, пиогенных гранулем, нарывной болезни, саркомы Капоши у пациентов со СПИД, системного склероза, глазных болезней, стойкого гиперпластического синдрома стекловидного тела, диабетической ретинопатии, ретинопатии недоношенных, неоваскуляризации сосудистой оболочки глаза, заболеваний легких, легочной гипертензии, астмы, носовых полипов, ринита, хронического восп�
Claims (9)
1. Применение пептида Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из васкулита и избыточного ангиогенеза при аутоиммунных заболеваниях, системного склероза, рассеянного склероза, синдрома Шегрена, мальформаций сосудов в сетях кровеносных и лимфатических сосудов, синдрома ДиДжорджа, врожденной геморрагической телеангиэктазии, пещеристой гемангиомы, кожной гемангиомы, мальформаций лимфатических сосудов, артериопатий трансплантата, атеросклероза, анастомозов сосудов, жировой ткани при ожирении, хронического отторжения аллотрансплантата, болезней кожи, псориаза, папиллом, аллергического дерматита, келоидных рубцов, пиогенных гранулем, нарывной болезни, саркомы Капоши у пациентов со СПИД, системного склероза, глазных болезней, стойкого гиперпластического синдрома стекловидного тела, диабетической ретинопатии, ретинопатии недоношенных, неоваскуляризации сосудистой оболочки глаза, заболеваний легких, легочной гипертензии, астмы, носовых полипов, ринита, хронического воспаления и обструкции дыхательных путей, кистозного фиброза, острого повреждения легких, формирующего пневмонию облитерирующего бронхиолита, заболеваний желудочно-кишечного тракта, пародонтоза, асцитов, перитонеальных спаек, циррозов печени, заболеваний репродуктивной системы, эндометриоза, маточного кровотечения, кист яичника, гиперстимуляции яичников, заболеваний костей и суставов, артрита и синовита, остеомиелита, образования костного нароста, индуцированного ВИЧ ангиогенеза в костном мозге, заболеваний почек, ранней диабетической нефропатии.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 совместно с, по меньшей мере, одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07017759 | 2007-09-11 | ||
EP07017759.7 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010114038A true RU2010114038A (ru) | 2011-10-20 |
Family
ID=40032721
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114038/15A RU2010114038A (ru) | 2007-09-11 | 2008-09-09 | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза |
RU2010114041/15A RU2010114041A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
RU2010113999/15A RU2010113999A (ru) | 2007-09-11 | 2008-09-09 | Применение секретина и необязательно уродилатина в качестве терапевтических средств |
RU2010114031/15A RU2010114031A (ru) | 2007-09-11 | 2008-09-09 | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114041/15A RU2010114041A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
RU2010113999/15A RU2010113999A (ru) | 2007-09-11 | 2008-09-09 | Применение секретина и необязательно уродилатина в качестве терапевтических средств |
RU2010114031/15A RU2010114031A (ru) | 2007-09-11 | 2008-09-09 | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства |
Country Status (8)
Country | Link |
---|---|
US (4) | US20100197588A1 (ru) |
EP (4) | EP2190533A2 (ru) |
JP (3) | JP2010539001A (ru) |
KR (3) | KR20100061478A (ru) |
AU (4) | AU2008303893A1 (ru) |
CA (4) | CA2698770A1 (ru) |
RU (4) | RU2010114038A (ru) |
WO (7) | WO2009040027A1 (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507540A (ja) | 2004-07-21 | 2008-03-13 | チューレン ユニバーシティ ヘルス サイエンス センター | Pacap化合物を用いる腎臓機能障害及び多発性骨髄腫の治療 |
US20110268789A1 (en) * | 2008-09-25 | 2011-11-03 | Min Li | Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents |
AU2009313619A1 (en) | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
US8637551B2 (en) | 2009-07-07 | 2014-01-28 | Merck Sharp & Dohme B.V. | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives |
WO2011054001A2 (en) | 2009-11-02 | 2011-05-05 | The Administrators Of The Tulane | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
US9962430B2 (en) | 2012-02-15 | 2018-05-08 | Chirhoclin, Inc. | Methods for treating pain associated with chronic pancreatitis |
US11406718B2 (en) | 2012-05-29 | 2022-08-09 | Chirhoclin, Inc. | Methods of detecting pancreobiliary ductal leaks |
TW201506036A (zh) * | 2013-08-14 | 2015-02-16 | Laurantis Pharma Oy | Vegf-c及ccbe1之治療用途 |
EP3035950A4 (en) * | 2013-08-14 | 2017-05-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
WO2017082707A1 (ko) * | 2015-11-13 | 2017-05-18 | 한양대학교 산학협력단 | 비강 투여를 통한 뇌졸중 치료용 조성물 |
JP6781974B2 (ja) * | 2016-03-31 | 2020-11-11 | 国立大学法人 宮崎大学 | アドレノメデュリン凍結乾燥製剤の製造方法 |
US11318190B2 (en) * | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
US20190287217A1 (en) * | 2018-03-13 | 2019-09-19 | Microsoft Technology Licensing, Llc | Machine learning system for reduced network bandwidth transmission of content |
US20230174607A1 (en) * | 2020-04-02 | 2023-06-08 | University Of Miyazaki | Novel Adrenomedullin Analog, Method for Producing the Same, and Pharmaceutical Use Thereof |
US11744878B2 (en) | 2020-08-19 | 2023-09-05 | Chirhoclin, Inc. | Methods for treatment of COVID-19 syndrome |
WO2022054826A1 (ja) * | 2020-09-09 | 2022-03-17 | 国立大学法人宮崎大学 | 抗ウイルス剤 |
WO2022054825A1 (ja) * | 2020-09-09 | 2022-03-17 | 国立大学法人宮崎大学 | ウイルス性感染症を有する対象における症状又は障害を予防又は治療するための医薬 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE454513B (sv) * | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
DE69128283T2 (de) | 1991-08-12 | 1998-03-19 | Nestle Sa | Nahrungsmittelzusammensetzung |
DE4216133A1 (de) * | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
JPH06228002A (ja) * | 1993-01-29 | 1994-08-16 | Takeda Chem Ind Ltd | Pacapを含有するセクレトグラニンιι産生促進剤 |
RU2130311C1 (ru) | 1994-05-06 | 1999-05-20 | Пфайзер Инк. | Лекарственные формы азитромицина с контролируемым высвобождением |
WO1996009318A1 (en) * | 1994-09-22 | 1996-03-28 | The Administrators Of The Tulane Educational Fund | Method and pharmaceutical composition for prevention and treatment of brain damage |
EP0845036B1 (en) * | 1995-08-18 | 1999-06-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
ES2197331T3 (es) | 1996-02-19 | 2004-01-01 | Amersham Health As | Medio de contraste estabilizado termicamente. |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
DE69608801T2 (de) | 1996-09-24 | 2000-10-12 | Nestle Sa | Milchaustauschprodukt und Verfahren zu dessen Herstellung |
WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
BR9915573B1 (pt) | 1998-11-24 | 2010-11-30 | processo de preparação de uma formulação infantil predominantemente a base de uma matéria-prima de leite oriunda de soro do leite, em que a composição em aminoácidos é semelhante àquela do leite humano. | |
GB0016441D0 (en) * | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
US6812210B2 (en) * | 2001-03-15 | 2004-11-02 | Research Development Foundation | Urocortin-III and uses thereof |
CA2444626A1 (en) * | 2001-04-18 | 2002-10-31 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
DE60128572T2 (de) | 2001-11-23 | 2008-02-07 | Société des Produits Nestlé S.A. | Verfahren zur Herstellung von Milchpulver und konzentrierten Milchprodukten |
US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
EP1575511A4 (en) * | 2002-11-07 | 2006-06-28 | Us Gov Health & Human Serv | NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY |
EP1578381A2 (en) * | 2002-12-24 | 2005-09-28 | The Board of Regents of The University of Texas System | Chemokine antagonists and uses thereof |
US8703693B2 (en) * | 2004-03-31 | 2014-04-22 | The Feinstein Institute For Medical Research | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
CA2477867A1 (en) * | 2004-09-17 | 2006-03-17 | Oncorex, Inc. | Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
US7507794B2 (en) * | 2005-02-08 | 2009-03-24 | Research Development Foundation | Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2) |
JP4830093B2 (ja) * | 2005-04-08 | 2011-12-07 | 国立大学法人 宮崎大学 | 非細菌性の炎症性疾患の予防又は治療剤 |
JP2006306770A (ja) * | 2005-04-27 | 2006-11-09 | Nidek Co Ltd | 眼疾患治療剤 |
EP1900374B1 (en) * | 2005-06-16 | 2014-03-12 | Takayuki Shindo | Angiogenetic agent containing adrenomedulin as the active ingredient |
US20090035287A1 (en) * | 2005-09-26 | 2009-02-05 | Zurit Levine | Atrial natriuretic peptide (anp) splice variants and methods of using same |
EP1951286A4 (en) * | 2005-10-07 | 2009-11-04 | Waratah Pharmaceuticals Inc | COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS |
WO2007044998A1 (en) * | 2005-10-12 | 2007-04-19 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
WO2007095737A1 (en) * | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
EP2114437A2 (en) * | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
-
2008
- 2008-09-09 RU RU2010114038/15A patent/RU2010114038A/ru not_active Application Discontinuation
- 2008-09-09 RU RU2010114041/15A patent/RU2010114041A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2698770A patent/CA2698770A1/en not_active Abandoned
- 2008-09-09 AU AU2008303893A patent/AU2008303893A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007736 patent/WO2009040027A1/en active Application Filing
- 2008-09-09 JP JP2010523374A patent/JP2010539001A/ja active Pending
- 2008-09-09 US US12/677,570 patent/US20100197588A1/en not_active Abandoned
- 2008-09-09 US US12/677,518 patent/US20100184676A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007709 patent/WO2009043481A2/en active Application Filing
- 2008-09-09 JP JP2010523420A patent/JP2010539047A/ja active Pending
- 2008-09-09 EP EP08802392A patent/EP2190533A2/en not_active Withdrawn
- 2008-09-09 AU AU2008303956A patent/AU2008303956A1/en not_active Abandoned
- 2008-09-09 JP JP2010523376A patent/JP5385277B2/ja not_active Expired - Fee Related
- 2008-09-09 RU RU2010113999/15A patent/RU2010113999A/ru not_active Application Discontinuation
- 2008-09-09 US US12/677,104 patent/US20100197586A1/en not_active Abandoned
- 2008-09-09 EP EP08785862A patent/EP2185179A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007542 patent/WO2009033700A1/en active Application Filing
- 2008-09-09 CA CA2698772A patent/CA2698772A1/en not_active Abandoned
- 2008-09-09 EP EP08802099A patent/EP2187939A1/en not_active Withdrawn
- 2008-09-09 CA CA2699153A patent/CA2699153A1/en not_active Abandoned
- 2008-09-09 AU AU2008297874A patent/AU2008297874A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007812 patent/WO2009046822A2/en active Application Filing
- 2008-09-09 KR KR1020107005596A patent/KR20100061478A/ko not_active Application Discontinuation
- 2008-09-09 CA CA2699167A patent/CA2699167A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007738 patent/WO2009040029A2/en active Application Filing
- 2008-09-09 EP EP08802267A patent/EP2197467A2/en not_active Ceased
- 2008-09-09 AU AU2008297542A patent/AU2008297542A1/en not_active Abandoned
- 2008-09-09 US US12/677,106 patent/US20100184674A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005598A patent/KR20100061479A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007544 patent/WO2009039994A1/en active Application Filing
- 2008-09-09 KR KR1020107005645A patent/KR20100059862A/ko not_active Application Discontinuation
- 2008-09-09 RU RU2010114031/15A patent/RU2010114031A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007881 patent/WO2009033767A2/en active Application Filing
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010114038A (ru) | Применение адреномедуллина в качестве терапевтического средства для лечения избыточного ангиогенеза | |
RU2010114048A (ru) | Применение пептида дефензина в качестве терапевтического средства | |
RU2010113967A (ru) | Применение родственного стресскопину пептида в качестве терапевтического средства | |
RU2010114004A (ru) | Применение меланиноконцентрирующего гормона и met-энкефалина в качестве терапевтических средств | |
RU2010113991A (ru) | Применение пептида галанина в качестве терапевтического средства | |
RU2010114029A (ru) | Астрессин и бета-эндорфин для применения в качестве терапевтических средств | |
RU2010114058A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113970A (ru) | Применение пептида phpfhlfvy (ингибитора ренина) в качестве терапевтического средства | |
RU2010113973A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114059A (ru) | Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства | |
RU2010113981A (ru) | Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств | |
RU2010114006A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113996A (ru) | Применение кальцитонина в качестве антиангиогенного средства | |
RU2010114033A (ru) | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv | |
RU2010114054A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113979A (ru) | Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv | |
RU2010114023A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
RU2010114052A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114008A (ru) | ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ГАСТРИНА 1 И G-Pen-GRGDSPCA | |
RU2010113984A (ru) | Применение врр-в в качестве терапевтического средства | |
RU2010114022A (ru) | Сочетание спленопентина и тимопентина и их применение в лекарственном средстве | |
RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |